Mission Statement, Vision, & Core Values of BioSig Technologies, Inc. (BSGM)

When you look at the foundational documents of BioSig Technologies, Inc. (BSGM), you see a mission to elevate cardiac care, but how does that square with the financial reality of a company that reported $0 million in revenue for the first six months of 2025? The company, which is now Streamex Corp. as of September 2025, posted a staggering net loss of over $(23.169) million in the first half of the year, all while sitting on just $2.8 million in cash as of June 30, 2025. Does a core value of innovation still apply when the entire business model pivots from medical devices to blockchain-based commodities tokenization? Let's dissect the original Mission Statement, Vision, and Core Values to see what they reveal about the company's past-and what they mean for its high-risk, high-reward future.

BioSig Technologies, Inc. (BSGM) Overview

You're looking for a clear picture of BioSig Technologies, Inc., and the reality is the company you knew just a few months ago is gone. The direct takeaway is this: BioSig Technologies, Inc. is no longer primarily a medical device company; it completed a massive strategic pivot in 2025 to become a blockchain-based commodities tokenization platform, now operating as Streamex Corp..

BioSig Technologies was founded in 2009, initially focusing on the cardiac electrophysiology (EP) market. Its flagship product, the PURE EP™ System, received FDA 510(k) clearance in 2018 and was designed to improve the fidelity of intracardiac signals, helping physicians perform more accurate cardiac ablation procedures. This system was its core product, and it was used in approximately 3,000 patient cases across the U.S. by early 2023.

However, the company fundamentally changed its business model in mid-2025 by merging with Streamex Exchange Corporation. This pivot shifted the focus from medical technology to Real World Asset (RWA) tokenization, starting with the global gold market. The corporate rebrand to Streamex Corp. and the new NASDAQ ticker symbol, STEX, became effective on September 12, 2025. The old product, PURE EP, is now a legacy asset as the company chases the high-risk, high-reward potential of digital commodities.

2025 Financial Performance: A Transformative Quarter

The latest financial reports, especially the Q3 2025 filing on November 14, 2025, show the stark financial reality of this pivot. The company's financial performance for the nine months ended September 30, 2025, reflects the transition, not a record-breaking sales period from the PURE EP System. The company reported $0 in revenue for both the third quarter and the nine-month year-to-date period.

Here's the quick math on the transition's cost: The net loss for the first nine months of 2025 was a significant $38.8 million, including a $15.6 million net loss in Q3 2025 alone. That's a massive burn rate without product sales. The balance sheet is materially weaker following the merger, with total assets rising to $130.5 million due to goodwill and intangible assets from the Streamex acquisition.

Still, the cash position did increase to $11.0 million as of the end of Q3 2025, but the company also carries a working capital deficit of $111 million. Honestly, this financial profile-no revenue and a huge working capital deficit-led management to disclose substantial doubt about the ability to continue as a going concern. That's a serious risk investors need to defintely consider.

• Q3 2025 Revenue: $0
• Nine-Month Net Loss: $38.8 million
• Q3 2025 Cash Position: $11.0 million
• Working Capital Deficit: $111 million

New Market Position: Leading the RWA Tokenization Charge

BioSig Technologies, Inc., now Streamex Corp., is aiming to be one of the leading companies in the nascent Real World Asset (RWA) tokenization industry, not the electrophysiology market. This is a full pivot, positioning the company as a high-growth, high-risk speculative play on digital commodities. They are building institutional-grade infrastructure to bring the gold and commodities market on-chain.

Their strategy involves a partnership with Monetary Metals to create tokenized yield-bearing gold products, which could generate up to a 4% return. This move is designed to disrupt the estimated $22 trillion global gold market. The company sees its NASDAQ listing as a unique advantage, providing established U.S. regulatory oversight that many other tokenization initiatives lack. That's the new game plan.

You can see the institutional interest is already shifting, with firms like LEGACY WEALTH MANAGMENT, LLC/ID adding shares in Q1 2025. To understand who is buying into this new vision and why, you should continue Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who's Buying and Why?

BioSig Technologies, Inc. (BSGM) Mission Statement

The core mission of BioSig Technologies, Inc. is to fundamentally elevate the standard of cardiac care by providing electrophysiologists with unprecedented clarity in signal data. This focus on signal purity is the bedrock of their long-term goals, even as the company has recently merged and rebranded to Streamex Corp. (STEX) to pursue a dual strategy that includes Real World Asset (RWA) tokenization.

The original mission, which still guides the PURE EP™ System division, aims to end the reliance on mixed signals and guesswork. It's a simple, but defintely powerful, idea: clearer signals mean better decisions, and better decisions save lives. That's the kind of clarity a seasoned analyst looks for in a growth strategy.

Here's the quick math on the need: The global electrophysiology market is projected to be worth $12.77 billion in 2025, and BioSig Technologies' mission is to capture a piece of that by solving the core technical problem of signal noise.

Component 1: Advancing Precision Cardiac Signal Acquisition and Analysis

This component is all about the technology-specifically, the PURE EP™ Platform's proprietary hardware and software combination. The mission mandates continuous innovation to acquire raw signal data in real-time, free from the noise and interference that plagues older systems. Precision is the non-negotiable starting point.

For example, the PURE EP™ System's commitment to signal hygiene has been clinically validated. In a blinded study published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated the PURE EP™ signals as superior to conventional systems for 75.2% of the samples reviewed, with 87% earning a rating of equivalent or superior.

The company's investment in this precision is clear in its subsidiary, BioSig AI Sciences, Inc., established to pursue AI-based diagnoses and therapies through the analysis of action potentials. As of June 30, 2025, BioSig Technologies held a majority interest of 84.5% in this forward-looking subsidiary.

Component 2: Improving the Accuracy and Efficacy of Cardiac Ablation Procedures

The mission translates precision into practical, clinical efficacy. The goal isn't just to show a clearer signal; it's to help the physician perform a better procedure. Ablation procedures, which treat heart rhythm disorders like atrial fibrillation, require the physician to target and ablate specific tissue with high confidence.

The PURE EP™ System's superior visualization is designed to enhance the accuracy of these procedures, leading to better patient outcomes. Independent research conducted by the Cleveland Clinic showed that the unique unipolar capabilities of the PURE EP™ System may cut procedure times by up to 66%. Shorter procedures mean less time under anesthesia and lower risk for the patient, plus more efficient use of expensive hospital lab time.

This focus on efficacy is what drives adoption. The PURE EP™ subscriber community includes world-class institutions like the Mayo Clinic and Cleveland Clinic, two of the top U.S. health systems in cardiology.

Component 3: Reducing Procedural Complications and Costs

The final pillar of the mission addresses the economic reality of healthcare. Technology must be clinically superior and financially viable. By enhancing the efficiency of the procedure, BioSig Technologies aims to reduce the overall burden on the healthcare system.

Here's the financial impact: Initial evidence suggested a potential cost saving of approximately $418.20 per procedure by leveraging the PURE EP™ System's clear signals. This is a direct, tangible return on investment for hospitals, which is critical for adoption in a competitive market.

To be fair, the company's financial profile leading up to the August 2025 strategic shift showed the need for this dual focus. For the six months ended June 30, 2025, BioSig Technologies reported a net loss of approximately $23.185 million, with cash on hand of $2.8 million. This financial reality is why the company executed an underwritten public offering in August 2025, raising approximately $15 million to fund a new strategy that includes gold bullion purchases and general corporate purposes, which you can read more about here: BioSig Technologies, Inc. (BSGM): History, Ownership, Mission, How It Works & Makes Money.

BioSig Technologies, Inc. (BSGM) Vision Statement

You're looking at the foundational documents of a company like BioSig Technologies, Inc. to understand its future, and that's the right move. The company's vision, as of late 2025, is a complex picture, split between its original medical technology ambition and a sharp, recent corporate pivot. The core vision remains rooted in achieving global leadership and clinical validation in electrophysiology, but the near-term action is focused on financial restructuring and a new business line.

Here's the quick math on the pivot: BioSig Technologies, Inc. reported a $0 million in total revenue for the first quarter of 2025, with a net loss of $(2.800) million. For a development-stage company, that cash burn is the immediate risk. So, while the vision for the PURE EP™ System is long-term, the company's September 2025 rebrand to Streamex Corp., focusing on Real World Asset (RWA) tokenization, shows a clear, decisive action to stabilize the balance sheet and pursue a new growth vector. The market capitalization, which stood at approximately $0.21 Billion USD as of November 2025, reflects the market's attempt to price this dual-focus entity. You need to assess the vision through both lenses.

Vision Component 1: Global Leadership in Electrophysiology

The vision of global leadership is tied directly to the commercial adoption of the PURE EP™ System, their proprietary advanced digital signal processing platform. This system is designed to improve the clarity of intracardiac signals (electrograms) during complex cardiac ablation procedures, which treat arrhythmias. The company's goal is to become the standard of care, not just a niche player. This is a tough fight, as the electrophysiology market is dominated by giants. Still, the PURE EP™ System has demonstrated strong clinical utility.

For example, the PURE EP™ Platform's technology was rated as superior to conventional systems for 75.2% of signal samples in a blinded clinical study, with 87% rated equivalent or superior. This clinical validation is the engine of the vision. Also, key institutions like Mayo Clinic-Phoenix and Cleveland Clinic, two of the top US health systems in cardiology, have adopted the PURE EP™ Platform, some under a new subscription model. That's a huge stamp of approval, but it hasn't translated to significant top-line growth yet; revenue for the six months ended June 30, 2025, was still negligible. The vision is sound, but the commercial execution is the risk. For more on the initial strategy, check out BioSig Technologies, Inc. (BSGM): History, Ownership, Mission, How It Works & Makes Money.

Mission: Unprecedented Accuracy and Patient Outcome Improvement

The mission is the 'why' behind the vision: to improve patient outcomes by providing unprecedented accuracy and clarity through their innovative signal processing platform. This is an empathetic, patient-centric mission that grounds the company's technology in a real-world clinical need. The core problem they address is the 'noise' in traditional electrophysiology signals, which can complicate ablation procedures and potentially lead to longer procedure times or less effective treatments.

The PURE EP™ System tackles this by providing ultra-pure, real-time cardiac signal data. Concrete data backs this up: independent research by Cleveland Clinic showed the PURE EP™ Platform's unique unipolar capabilities may cut procedure times by up to 66%. Shorter procedure times mean less risk for the patient, plus substantial cost savings for the hospital. Initial evidence suggested potential savings of approximately $418.20 per procedure using the clearer signals. This is a mission that directly maps technology to clinical and economic results. That's a defintely powerful combination.

Core Values: Innovation, Integrity, and Collaboration

A company's core values show you how they intend to achieve their mission and vision. BioSig Technologies, Inc.'s values center on the process of medical technology development and adoption:

• Innovation: Constantly seeking new ways to advance electrophysiology. This is evident in their shift from hardware commercialization to the research and development of novel software algorithms for the PURE EP™ Platform.
• Integrity: Upholding the highest ethical standards and ensuring transparency. This is non-negotiable in the medical device space, especially when dealing with patient data and clinical trials.
• Collaboration: Working closely with clinicians, researchers, and industry partners. The partnerships with major centers like Mayo Clinic and Cleveland Clinic are the clearest example of this value in action, leading to clinical data validation.

To be fair, the Q2 2025 loss from operations of $(20.365) million shows the massive financial pressure that led to the corporate change. The new business focus on Real World Asset tokenization, while a necessary financial maneuver, will test the 'integrity' and 'passion' of the team as they balance two vastly different market focuses-medtech and blockchain-under one corporate roof. The original core values still apply to the PURE EP™ business, but the investor focus has undeniably broadened.

The next step for you is clear: Finance needs to model the projected cash flow from the new Streamex Corp. business line against the historical burn rate of the PURE EP™ segment by the end of this quarter.

BioSig Technologies, Inc. (BSGM) Core Values

You're looking for the guiding principles of BioSig Technologies, Inc., and honestly, the company's core values have undergone a massive, high-stakes stress test this year. The firm, which recently merged with Streamex Exchange Corporation and now operates as Streamex Corp. (STEX) as of September 2025, has pivoted from a medical device focus to a real-world asset (RWA) tokenization platform. This move didn't just change the business model; it redefined what the company values. We're mapping the old ethos onto the new, high-growth, high-risk world of digital commodities.

The core values now center on the new mission: unlocking liquidity and transparency in the massive commodities market. This is a complete strategic overhaul, backed by significant capital, so let's look at the new values and the 2025 actions that prove them.

Innovation & Strategic Transformation

Innovation is no longer just about a better signal processor; it's about fundamentally reshaping global finance. BioSig Technologies, Inc. (BSGM) demonstrated this value not with a product update, but with a full-scale corporate pivot in mid-2025. That's a bold, defintely non-cliché move.

The company's commitment to innovation is evident in its new proprietary real-world asset (RWA) platform. This technology aims to bring the approximately $142 trillion commodities market onto the blockchain, starting with gold. This strategic transformation is the clearest example of their core value in action. Here's the quick math on the shift:

• Legacy Revenue (FY 2024): Approximately $40K.
• New Market Target: The $142 trillion commodities market.
• Action: Deprioritizing the PURE EP™ medical device system.

The entire business now hinges on this innovative, transformative strategy, moving from a niche medical technology to a fintech disruptor. You can learn more about the stakeholders driving this change by Exploring BioSig Technologies, Inc. (BSGM) Investor Profile: Who's Buying and Why?

Transparency & Accessibility

In the world of finance, transparency and accessibility are critical, especially when dealing with real-world assets (RWAs). The company's mission explicitly includes unlocking 'liquidity, transparency, and accessibility' across the commodities market. This value is about making historically opaque and illiquid assets, like physical gold, tradable and visible on a decentralized ledger.

The primary action supporting this value in 2025 was the massive capital raise intended to secure physical assets. The company secured a $1.1 billion funding commitment in July 2025, comprising $100 million in senior secured convertible debentures and a $1 billion Equity Line of Credit. The stated use of proceeds from a subsequent August 2025 public offering, which raised approximately $15 million, was to purchase gold bullion. This directly links their financial maneuvers to the core value of grounding their digital assets in a transparent, tangible store of value.

Financial Discipline & Trust

A company that pivots needs to earn trust fast, and in finance, that means showing discipline and securing a strong foundation. The 'Trust' value is built on two pillars: the stability of their underlying asset and their commitment to regulatory compliance.

The first pillar is the gold-backed treasury management strategy, which aims to be 'grounded in what we believe to be the world's most trusted store of value'. The second pillar is governance. Despite the dramatic pivot, the company maintained its listing on The Nasdaq Capital Market, with formal approval granted in October 2025 under the new ticker STEX. This is a crucial vote of confidence from a major regulatory body. What this estimate hides, however, is the financial reality of the transition: the company reported a net loss of approximately -$2.8 million in the first quarter of 2025, which underscores the high cost of this transformation and the need for the new revenue model to start delivering.

Next step: The executive team needs to announce the first successful tokenization and exchange of a physical gold asset on their platform before the end of Q4 2025.